| Ultimaster Nagomi™ and Ultimaster™ Tansei™ are now MDR certified for patients at high bleeding risk. | https://www.terumo-europe.com/en-emea/news/ultimaster-nagomi™-and-ultimaster™-tansei™-are-now-mdr-certified-for-patients-at-high-bleeding-risk | Ultimaster Nagomi™ and Ultimaster™ Tansei™ are now MDR certified for patients at high bleeding risk. | | 3/6/2025 11:00:00 PM | <p>Terumo Europe announces today that it has received MDR approval for an expanded indication of its Ultimaster Nagomi™ and Ultimaster™ Tansei™ sirolimus eluting coronary stent systems.<br></p> |
| Terumo Launches its Injection Filter Needle, a first step of the INFINO™ -Development Program, to extend the choice for hypodermic and intravitreal injections. | https://www.terumo-europe.com/en-emea/news/terumo-launches-its-injection-filter-needle-a-first-step-of-the-infino™-development-program-to-extend-the-choice-for-hyp | Terumo Launches its Injection Filter Needle, a first step of the INFINO™ -Development Program, to extend the choice for hypodermic and intravitreal injections. | | 1/14/2025 11:00:00 PM | <h4><br><br></h4> |
| NICE PUBLISHES NEW GUIDANCE SUPPORTING THE USE OF HOLMIUM-166 SELECTIVE INTERNAL RADIATION THERAPY FOR UNRESECTABLE ADVANCED HEPATOCELLULAR CARCINOMA | https://www.terumo-europe.com/en-emea/news/nice-publishes-new-guidance-supporting-the-use-of-holmium-166-selective-internal-radiation-therapy-for-unresectable-advance | NICE PUBLISHES NEW GUIDANCE SUPPORTING THE USE OF HOLMIUM-166 SELECTIVE INTERNAL RADIATION THERAPY FOR UNRESECTABLE ADVANCED HEPATOCELLULAR CARCINOMA | | 7/2/2024 10:00:00 PM | <h4>Terumo Europe delighted to share that a positive guidance has been published by NICE mentioning that Holmium-166 Selective Internal Radiation Therapy (SIRT) using QuiremSpheres<sup>TM</sup> microspheres is recommended as an option for treating HCC patients with child-Pugh grade A liver impairment, when conventional transarterial therapies are inappropriate. <br></h4> |
| NICE publishes a guidance supporting the use of Selective Internal Radiation Therapy for neuroendocrine tumors with liver metastasis | https://www.terumo-europe.com/en-emea/news/nice-publishes-a-guidance-supporting-the-use-of-selective-internal-radiation-therapy-for-neuroendocrine-tumors-with-liver-m | NICE publishes a guidance supporting the use of Selective Internal Radiation Therapy for neuroendocrine tumors with liver metastasis | | 5/16/2024 10:00:00 PM | <h4><br><br></h4><h4>Terumo Europe is delighted to share that a positive guidance has been published by NICE stating that Selective Internal Radiation Therapy (SIRT) is now recommended to be used for the treatment of neuroendocrine tumors with liver metastasis (NELM).<br></h4><h4>This is a key milestone as it expands the existing treatment options (surgery, percutaneous ablation, systemic therapies, peptide receptor radionuclide therapy (PRRT) & other intra-arterial therapies) for the treatment of patients with NELM. <br></h4> |
| Launch BioPearlTM microspheres, the first resorbable drug-eluting microspheres | https://www.terumo-europe.com/en-emea/news/launch-biopearltm-microspheres-the-first-resorbable-drug-eluting-microspheres | Launch BioPearlTM microspheres, the first resorbable drug-eluting microspheres | | 4/28/2024 10:00:00 PM | <h4>Terumo Europe N.V. is pleased to announce the launch of BioPearl<sup>TM</sup> microspheres, the first resorbable drug-eluting microspheres. We are continuing our commitment to advancing TACE by adding our latest innovation and to expanding your TACE therapeutic options. BioPearl<sup>TM</sup> microspheres are designed to combine the confidence from the drug-eluting microspheres technology and the benefits of a resorbable agent.<br></h4> |
| Launch of new multi-center study investigating resorbable drug-eluting microspheres safety and efficacy | https://www.terumo-europe.com/en-emea/news/launch-of-new-multi-center-study-investigating-resorbable-drug-eluting-microspheres-safety-and-efficacy | Launch of new multi-center study investigating resorbable drug-eluting microspheres safety and efficacy | | 3/10/2024 11:00:00 PM | <p><span lang="EN-GB" style="font-family:"segoe ui", sans-serif;"></span><span lang="EN-GB" style="font-family:"segoe ui", sans-serif;">Terumo Europe N.V. announces the launch of the BIOPEARL-ONE study, a new multi-center post market clinical trial: BioPearl<sup>TM</sup> microspheres are loaded with doxorubicin to treat patients with unresectable hepatocellular carcinoma (HCC). A prospective, single arm, multi-centre post-market follow-up study is intended to assess the safety and efficacy of BioPearl<sup>TM</sup> microspheres loaded with doxorubicin in the treatment of patients with unresectable HCC. </span><br></p> |
